Answers are grounded in this paper and cite their sources.
Pulmonary hypertension (PH) secondary to left heart disease (group II) is a fatal syndrome and the most prevalent form of PH. PH-II is characterized by an increase in total pulmonary vascular resistance (TPVR). Recent studies in patients found an association between remodeling of small-diameter pulmonary veins (SPV) and the severity of PH-II, suggesting that increased SPV contractility and/or remodeling may contribute to increased TPVR. Purinergic agonists can induce contraction and vascular remodeling via purinergic receptors on vascular smooth muscle cells, and purinergic receptor signaling is implicated in other forms of PH. Thus, we hypothesized that PH-II alters purinergic receptors in SPV, contributing to increased TPVPR. The study of PH-II is limited due to the lack of suitable experimental models. Therefore, we first evaluated three experimental strategies to induce PH-II in rats: abdominal aortic constriction, renovascular hypertension, and transverse aortic constriction (TAC). Physiologic, echocardiographic, morphometric, and molecular biology studies indicated that only TAC rats developed PH-II. Next, we evaluated whether TAC-induced PH-II modified the contractile response to purinergic agonists in SPV. Studies in precision-cut lung slices showed that SPV from TAC-induced HP-II presented an increased contractile response to UTP. Both lung tissue and laser-microdissected SPV from TAC-induced PH-II rats showed higher purinergic receptor expression as compared with lung tissue and SPV from control rats. Also, lungs from TAC-induced PH-II rats showed SPV hypertrophy and SPV wall remodeling, associated with perivascular/peribronchial immune cell infiltration. These results suggest that purinergic receptors of SPV are implicated in PH-II development.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: